



## Ressources : Documentation de référence sur le DMPA sous-cutané

Le DMPA sous-cutané (DMPA-SC) est un produit innovateur qui simplifie l'administration de la contraception injectable. La plupart des ressources proposées ci-dessous font référence à Sayana® Press — un produit DMPA-SC fabriqué par Pfizer Inc. qui combine le médicament et l'aiguille en un simple dispositif tout-en-un. Remarquez que la grande majorité des ressources proposées ne sont disponibles qu'en anglais.

### Le DMPA-SC représente une option contraceptive hautement efficace et sûre.

[The coming-of-age of subcutaneous injectable contraception](#) Global Health: Science and Practice 2018

[Sayana® Press clinical brief](#) PATH 2017

[Medical eligibility criteria for contraceptive use](#) World Health Organization (WHO) 2015

[Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm](#) Contraception 2014

[Progestin-only contraception: Injectables and implants](#) Best Practice & Research Clinical Obstetrics & Gynaecology 2014

[Sayana® Press: Can it be a “game changer” for reducing unmet need for family planning?](#) Contraception 2014


### Les prestataires de la planification familiale et les clientes apprécient le DMPA-SC.

[Expanding access to injectable contraception: Results from pilot introduction of subcutaneous depot medroxyprogesterone acetate \(DMPA-SC\) in 4 African countries](#) Global Health: Science and Practice 2018

[Monitoring Sayana Press pilot introduction](#) PATH 2017

[Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal](#) Contraception 2014

[Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: A randomized crossover trial](#) Contraception 2014



### Les faits, en bref (Sayana® Press)

- **99 pour cent efficace pour prévenir les grossesses non désirées** avec une administration correcte et opportune, tous les trois mois. Aucune protection contre le VIH et les autres infections sexuellement transmissibles.
- **Moindre dose d'hormone contraceptive** que DMPA intramusculaire.
- **Compact et léger, avec une aiguille courte.**
- **Facile à utiliser, même pour les agents de santé communautaire et les femmes elles-mêmes (auto-administration).**
- **Stable à température ambiante (15°C–30°C).**
- **Durée de conservation de trois ans.**
- **Disponible dans plus de 20 pays FP2020\*.**
- **Offert au prix de USD 0,85 par dose** aux acheteurs qualifiés (y compris le ministère de la santé dans les pays FP2020).

\* L'initiative FP2020 cherche à élargir l'accès à l'information, aux services et aux produits de la planification familiale à 120 millions de femmes et de filles de plus dans les 69 pays les plus pauvres du monde.



PATH/WILL Boase

**Provider acceptability of Sayana® Press: Results from community health workers and clinic-based providers in Uganda and Senegal**  
Contraception 2014

**Acceptability of Depo-subQ in Uniject, now called “Sayana Press”**  
FHI 360 2013

**Le DMPA-SC peut être administré avec succès par les agents de santé communautaire.**

**Expanding access to injectable contraception: Results from pilot introduction of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in 4 African countries** Global Health: Science and Practice 2018

**Monitoring Sayana Press pilot introduction** PATH 2017

**Injections and beyond: Training community health workers to provide contraception in Uganda** PATH 2016 (See Presentation 3)

**Pilot research as advocacy: The case of Sayana Press in Kinshasa, Democratic Republic of the Congo** Global Health: Science and Practice 2016

**Task shifting in Sayana Press introduction in the Democratic Republic of Congo (DRC)** Tulane University DRC 2016 (See Presentation 2)

**Community health workers: Bringing family planning services to where people live and work** High Impact Practices (HIP) 2015

**Operational assessments of Sayana® Press provision in Senegal and Uganda** Contraception 2014

**Feasibility of administering Sayana® Press in clinics and communities: Summary findings from an operational assessment in Senegal** PATH 2013

**Operational assessment: Administration and management of Sayana® Press in clinics and communities in Uganda** PATH 2013

**Global experience of community health workers for delivery of health related Millennium Development Goals: A systematic review, country case studies, and recommendations for integration into national health systems** Global Health Workforce Alliance 2010

**Community-based health workers can safely and effectively administer injectable contraceptives** WHO 2009



PATH/Will Boase

**Le DMPA-SC peut élargir les options mises à la disposition des femmes qui n'ont jamais encore pratiqué la contraception.**

[Monitoring Sayana Press pilot introduction](#) PATH 2017

[Introducing the next generation injectable in Nigeria](#)  
DKT Nigeria 2016

**Les femmes peuvent s'auto-administrer le DMPA-SC sous formation et accompagnement. Elles jugent l'auto-administration acceptable.**

[Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate \(DMPA\) in Senegal: a prospective cohort study](#) Contraception 2017

[A prospective cohort study of the feasibility and acceptability of depot medroxyprogesterone acetate administered subcutaneously through self-injection](#) Contraception 2016

[Stakeholder views on self-injection of DMPA-SC in Senegal and Uganda](#) PATH 2016

[Health worker roles in providing safe abortion care and post-abortion contraception](#) WHO 2015 (Page 62)

[Pfizer's Sayana® Press becomes first injectable contraceptive in the United Kingdom available for administration by self-injection](#)  
Pfizer 2015

[Home-based administration of Sayana® Press: Review and assessment of needs in low-resource settings](#) Contraception 2014

[Perceptions of home and self-injection of Sayana® Press in Ethiopia: A qualitative study](#) Contraception 2014

[Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate](#)  
Contraception 2014

[Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception](#)  
Contraception 2012

[Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: Feasibility and acceptability](#)  
Contraception 2012

[Home-based administration of depo-subQ provera 104™ in the Uniject™ injection system: A literature review](#) PATH 2011

[Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women](#) Contraception 2010

[The acceptability of self-administration of subcutaneous Depo-Provera](#) Contraception 2005

[Self-administration with UniJect® of the once-a-month injectable contraceptive Cyclofem®](#) Contraception 1997

**Les femmes qui s'auto-administrent le DMPA-SC ont une plus forte taux de continuation que les femmes qui reçoivent des injections aux niveaux d'un prestataire.**

[Continuation of injectable contraception when self-injected v. administered by a facility-based health worker: A non-randomized, prospective cohort study in Uganda](#) Contraception 2018

[Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial](#) The Lancet Global Health 2018

[DMPA self-administration can improve contraceptive access, continuation, and autonomy](#) The Lancet Global Health 2018

[Increased 1-year continuation of DMPA among women randomized to self-administration: results from a randomized controlled trial at Planned Parenthood](#) Contraception 2018

**Le DMPA-SC peut offrir une option appropriée de prestation en pharmacie ou *drug shop*, ainsi que dans le cadre d'initiatives de marketing social.**

[Experience with DMPA-SC: Social marketing in Bangladesh](#) Social Marketing Company 2017

[Introducing the next generation injectable in Nigeria](#) DKT Nigeria 2016

[Key role of \*drug shops\* and pharmacies for family planning in urban Nigeria and Kenya](#) Global Health: Science and Practice 2016

[Drug shops and pharmacies: Sources for family planning commodities and information](#) HIP 2013

[WHO recommendations: Optimizing health worker roles to improve access to key maternal and newborn health interventions through task shifting](#) WHO 2012

## Ressources

## complémentaires

### Données relatives à la prestation du DMPA-SC à travers les programmes de planification familiale

[Family planning - A global handbook for providers](#) WHO 2018

[DMPA-SC introduction and scale-up in Nigeria: Future benefits for contraceptive use and savings](#) Health Policy Plus 2018

[Rapid uptake of the subcutaneous injectable in Burkina Faso: Evidence from PMA2020 cross-sectional surveys](#)

Global Health: Science and Practice 2018

[How to introduce and scale up Sayana Press \(DMPA-SC in Uniject\)](#) PATH 2017

[Advancing community-based access to Sayana Press: Expanding the reach of the formal health system](#)

Advancing Partners & Communities 2016

[Training doesn't end there: Lessons learned from supportive supervision of providers offering a new injectable contraceptive in Burkina Faso](#) UNFPA Burkina Faso

2016 (See Presentation 1)

### Ressources sur le DMPA et le VIH

[Guidance statement: Hormonal contraceptive eligibility for women at high risk of HIV](#) WHO 2017

[Hormonal contraceptive eligibility for women at high risk of HIV: Frequently asked questions](#) WHO 2017

[Hormonal contraceptives and HIV – An introductory fact sheet](#) AVAC 2017

[What is up with DMPA and “grades” for family planning?](#)

(A plain language explanation) AVAC 2017

[An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women](#) AIDS 2016

[Strategic communication framework for hormonal contraceptive methods and potential HIV-related risks](#) Health Communication Capacity Collaborative 2016

[Medical eligibility criteria for contraceptive use](#) WHO 2015